ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Safety of Sofosbuvir and Daclatasvir in Patients having Ischemic Heart Disease for Treatment of HCV Compensated Cirrhosis |Biomedgrid

Journal: American Journal of Biomedical Science & Research (Vol.9, No. 4)

Publication Date:

Authors : ; ; ; ; ;

Page : 340-345

Keywords : HCV ischemic patients; Sofosbuvir in ischemia; CIMT; Medical; Liver transplantation;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Various biomarkers were used to evaluate the progression and prognosis of atherosclerosis. Safety of new therapeutic modalities of HCV needs more systematic studies. 80 patients were enrolled in our study to demonstrate the safety margin of the the new treatment of HCV in the form of Sofosbuvir and Daclatasvir in patients with coronary artery disease. CIMT, as well as different biomarkers that predict progression of atherosclerosis were analyzed at the beginning of therapy and after receiving the final dose.

Last modified: 2023-06-19 21:23:26